CTAS vs CURX · P/E 51, rev $11.26B vs $8.9M cap
Cintas Corporation (CTAS) versus Curanex Pharmaceuticals Inc Common Stock (CURX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Curanex Pharmaceuticals Inc Common Stock (CURX) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
CURX does not have a complete income-statement cache yet.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. CURX currently screens at market cap $8.9M.
Not investment advice. Open the CTAS and CURX stock pages for the full models.
Not investment advice.